Advertisement
Australia markets open in 2 hours 45 minutes

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • AUD/USD

    0.6521
    +0.0021 (+0.32%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    83.77
    +0.96 (+1.16%)
     

  • GOLD

    2,344.60
    +6.20 (+0.27%)
     

  • Bitcoin AUD

    99,676.48
    +1,362.09 (+1.39%)
     

  • CMC Crypto 200

    1,398.50
    +15.93 (+1.15%)
     

What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?

Brian Orelli, PhD and Keith Speights, The Motley Fool
·5-min read

Vertex Pharmaceuticals (NASDAQ: VRTX) has $6.6 billion in the bank and continues to generate more cash flow each quarter. While Vertex has some early stage drugs that could generate revenue in a few years, the company is also looking to buy growth through the acquisition of a late-stage pipeline candidate or two (or three). In this video from Motley Fool Live recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss the biotech's pipeline and where it might expand beyond cystic fibrosis.

Continue reading